The global aptamers market in terms of revenue was estimated to be worth $151 million in 2021 and is poised to reach $342 million by 2026, growing at a CAGR of 17.7% from 2021 to 2026.
Download PDF Brochure:
Key Market Players:
Aptamer Group (UK), Raptamer Discovery Group (US), SomaLogic Inc., (US), Aptamer Sciences, Inc. (South Korea), Aptagen, LLC (US), Maravai Lifesciences (US), Kaneka Corporation (Japan), NeoVentures Biotechnology Inc. (Canada), Aptus Biotech (Spain), Base Pair Biotechnologies (US), AMSBIO (UK), Novaptech (France), Bio-Techne (US)
Browse in-depth TOC on "DNA Aptamers Industry"
196 – Tables
38 – Figures
183 – Pages
Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics.
Lower production cost and higher stability will drive the DNA-based aptamers segment growth
Based on type, the aptamers market is segmented into DNA aptamers, XNA aptamers, and RNA aptamers. The DNA-based aptamers segment dominated the market in 2020. The large share of this segment is attributed to their lower production cost and higher stability compared to other nucleic acid-based aptamers and the wide availability of DNA aptamers.
Request Free Sample Pages:
The therapeutics development segment will continue to dominate the aptamers market during the forecast period
Based on the application, the market is segmented into therapeutics development, research & development, diagnostics, and other applications. The therapeutics development segment dominated the market due to the increasing number of clinical trials evaluating aptamers for new therapies and collaborations among aptamer companies & prominent pharmaceutical and biotechnology firms. The diagnostic segment is projected to grow at the highest CAGR due to the increasing prevalence of chronic diseases and the development of new diagnostic kits to detect cancer and other diseases.
Pharmaceutical & biotechnology companies are the largest end users of aptamers market
Based on end user, the market is segmented into pharmaceutical companies & biotechnology companies, academic & government research institutes, contract research organizations, and other end users. Pharmaceutical & biotechnology companies dominated the market owing to the increasing number of market players offering custom aptamers for use in therapeutics development & rising R&D expenditure. The diagnostic segment will record the highest CAGR during the forecast period due to the development of diagnostic tools for cancer and infectious diseases.
Others segment is expected to witness the highest CAGR during the forecast period
Based on technology, the aptamers market is segmented into SELEX and other technologies. The SELEX technology segment dominated the market in 2020. The segment accounts for a large share of the aptamers market as SELEX is one of the most widely used technologies. The other technologies segment is expected to register the highest CAGR during the forecast period due to the increasing focus on developing technologies for aptamer selection.
North America was the largest regional market for aptamers market in 2020
The global aptamers market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The largest share of North America is attributed to the availability of funds to develop innovative technologies, the presence of prominent market players, and growing collaborations among companies.
Hypothetic Challenges of Aptamers Market in Near Future:
Increased Competition: With the growing popularity of aptamers, more companies are entering the market and competing for market share. This could lead to increased competition and price wars, which could make it difficult for existing companies to remain profitable.
Regulatory Uncertainty: With the technology being relatively new, regulatory frameworks for aptamers are not yet established in many countries. This could lead to uncertainty in the market and could prevent companies from being able to make long-term plans.
Technological Limitations: The current technology behind aptamers is limited in terms of its capabilities. This could lead to a lack of innovation and progress in the market, which could hinder its potential growth.
Cost of Production: The cost of producing aptamers is relatively high due to the complexity of the technology. This could make it difficult for companies to remain competitive and profitable.
Safety Concerns: As with any medical technology, there are always safety concerns surrounding the use of aptamers. This could lead to increased scrutiny and potential legal issues, which could further complicate the market.
Top 3 Use Cases of Aptamers Market:
Diagnostics: Aptamers can be used in various diagnostic applications, such as antigen-antibody assays, DNA/RNA detection, and enzyme assays. Aptamers can also be used to detect drug residues in food and water.
Therapeutics: Aptamers can be used as therapeutic agents to target specific cells and tissues, as well as to deliver drugs directly to their site of action. They can also be used as molecular “scissors” to cleave specific proteins or DNA sequences.
Research: Aptamers are widely used in research applications such as protein structure determination, gene expression profiling, protein-protein interaction studies, and gene silencing. They are also used to study cellular processes such as apoptosis and cell-signalling pathways.
Recent Developments
In August 2021, Aptamer Group, Ltd. and BizCom Japan, Inc. entered into a distribution and marketing agreement to market Optimer discovery and development services in Japan.
In August 2021, Aptamer Group entered a partnership with ProAxsis Limited. As per the partnership, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsiss diagnostic assays
In July 2021, Aptamer Sciences, Inc. was selected by the Korean government to support a non-clinical project for a new drug development project for COVID-19 treatment and vaccine and will receive a research grant of about USD 0.51 million for one year through this project.
Get 10% Free Customization on this Report:
Comments